Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma

Hye Ryun Kim, Chang Geol Lee, Eun Chang Choi, Joo Hang Kim, Yoonwoo Koh, ByoungChul Cho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel-S-1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. Method Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S-1, followed by 7 cycles of RT with concurrent daily cisplatin. Results The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14%). Forty of 50 patients who completed induction chemotherapy with docetaxel and S-1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S-1. The best response to induction chemotherapy with docetaxel and S-1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5% and complete response in 47.5%, respectively. With a median follow-up of 61 months, 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 65.7%, respectively. Conclusion Administration of induction chemotherapy with docetaxel and S-1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT.

Original languageEnglish
Pages (from-to)E1653-E1659
JournalHead and Neck
Volume38
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

docetaxel
Induction Chemotherapy
Cisplatin
Neck
Radiotherapy
Head
Carcinoma
Chemoradiotherapy
Neutropenia
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Otorhinolaryngology

Cite this

@article{4563588060154d25a8e7704572e73273,
title = "Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma",
abstract = "Background The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel-S-1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. Method Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S-1, followed by 7 cycles of RT with concurrent daily cisplatin. Results The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14{\%}). Forty of 50 patients who completed induction chemotherapy with docetaxel and S-1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S-1. The best response to induction chemotherapy with docetaxel and S-1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5{\%} and complete response in 47.5{\%}, respectively. With a median follow-up of 61 months, 5-year progression-free survival (PFS) and overall survival (OS) were 63.3{\%} and 65.7{\%}, respectively. Conclusion Administration of induction chemotherapy with docetaxel and S-1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT.",
author = "Kim, {Hye Ryun} and Lee, {Chang Geol} and Choi, {Eun Chang} and Kim, {Joo Hang} and Yoonwoo Koh and ByoungChul Cho",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/hed.24294",
language = "English",
volume = "38",
pages = "E1653--E1659",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",

}

Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma. / Kim, Hye Ryun; Lee, Chang Geol; Choi, Eun Chang; Kim, Joo Hang; Koh, Yoonwoo; Cho, ByoungChul.

In: Head and Neck, Vol. 38, 01.04.2016, p. E1653-E1659.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma

AU - Kim, Hye Ryun

AU - Lee, Chang Geol

AU - Choi, Eun Chang

AU - Kim, Joo Hang

AU - Koh, Yoonwoo

AU - Cho, ByoungChul

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel-S-1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. Method Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S-1, followed by 7 cycles of RT with concurrent daily cisplatin. Results The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14%). Forty of 50 patients who completed induction chemotherapy with docetaxel and S-1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S-1. The best response to induction chemotherapy with docetaxel and S-1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5% and complete response in 47.5%, respectively. With a median follow-up of 61 months, 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 65.7%, respectively. Conclusion Administration of induction chemotherapy with docetaxel and S-1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT.

AB - Background The purpose of this study was to assess the efficacy and safety of induction chemotherapy with docetaxel-S-1, and radiotherapy (RT) with concurrent daily cisplatin in locally advanced head and neck carcinoma. Method Fifty patients received 2 cycles of induction chemotherapy with induction chemotherapy with docetaxel and S-1, followed by 7 cycles of RT with concurrent daily cisplatin. Results The most frequent grade 3 to 4 hematologic toxicity was neutropenia (14%). Forty of 50 patients who completed induction chemotherapy with docetaxel and S-1 subsequently started RT with concurrent daily cisplatin, all within 3 to 4 weeks after the start of the second cycle of induction chemotherapy with docetaxel and S-1. The best response to induction chemotherapy with docetaxel and S-1 and after completion of RT with concurrent daily cisplatin was partial response (PR) in 52.5% and complete response in 47.5%, respectively. With a median follow-up of 61 months, 5-year progression-free survival (PFS) and overall survival (OS) were 63.3% and 65.7%, respectively. Conclusion Administration of induction chemotherapy with docetaxel and S-1 before RT with concurrent daily cisplatin chemoradiotherapy (CRT) resulted in a high response rate with good tolerability, and did not compromise subsequent CRT.

UR - http://www.scopus.com/inward/record.url?scp=84975784446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975784446&partnerID=8YFLogxK

U2 - 10.1002/hed.24294

DO - 10.1002/hed.24294

M3 - Article

VL - 38

SP - E1653-E1659

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -